Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: A multicenter real-world study in Spain
- 27 May 2025
- journal article
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 84-89
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Treatment simplification to optimize cenobamate effectiveness and tolerability: A real‐world retrospective study in SpainEpilepsia Open, 2024
- Cenobamate in patients with highly refractory focal epilepsy: A retrospective real-world studySeizure: European Journal of Epilepsy, 2023
- Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access ProgramEpilepsia Open, 2023
- Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut SyndromeJAMA Neurology, 2022
- Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medicationsEpilepsia, 2021
- Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trialThe Lancet Neurology, 2020
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut SyndromeNew England Journal of Medicine, 2018
- Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2018
- Long-term prognosis of patients with Lennox–Gastaut syndrome in recent decadesEpilepsy Research, 2015
- Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodologyThe Lancet Neurology, 2009